Vol 9 (2024): Continuous Publishing
Original paper
Published online: 2024-05-02

open access

Page views 66
Article views/downloads 31
Get Citation

Connect on Social Media

Connect on Social Media

Effect of needle size on pain degree and intraocular pressure after intravitreal injection: a randomized observational study

Ali Altan Ertan Boz1, Sücattin İlker Kocamış2, Kadriye Demir Boncukçu1, Meryem Dilara Kılıç1, Halil İbrahim Sönmezoğlu1, Erkan Çelik1
Ophthalmol J 2024;9:86-91.

Abstract

BACKGROUND: Intravitreal injection (IVI) is a common vitreoretinal procedure, and in most patients, multiple IVIs related to the course of their disease have to be performed. Pain sensations during IVI can reduce the desire to continue repeated IVI and can cause complications due to sudden eye movements. The purpose of this study was to compare the effect of needle size on immediate intraocular pressure (IOP), vitreous reflux, and pain experienced in patients after the IVI procedure.

MATERIAL AND METHODS: One hundred and ten eyes of 110 patients who were first administered intravitreal ranibizumab or aflibercept were randomized according to the needle size, 30-gauge (Group 1) or 26-gauge (Group 2). The reflux was graded per the IVI procedure. Immediately after IVI, patients were asked to assess the degree of pain with a visual analogue scale (VAS). The IOP measurements were performed 30 minutes after the operation. The average of VAS scores was used as the primary outcome.

RESULTS: Both groups consisted of 55 eyes. The mean VAS score was 2.18 ± 1.82 in Group 1 and 4.00 ± 2.36 in Group 2. The mean vitreous reflux was lower in Group 1 than in Group 2. The mean IOP was comparable between the groups (26.3 ± 5.66/25.4 ± 4.02 mm Hg). The groups were divided into subgroups according to intravitreal agent use; no statistical difference was observed in VAS scores.

CONCLUSIONS: The 30-gauge needle was more comfortable and safer than the 26-gauge needle for the IVI procedure.

Article available in PDF format

View PDF Download PDF file

References

  1. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009; 29(7): 875–912.
  2. Li A, Veerappan M, Mittal V, et al. Anti-VEGF agents in the management of diabetic macular edema. Exp Rev Ophthalmol. 2020; 15(5): 285–296.
  3. Jiang Yi, Mieler WF. Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions. Asia Pac J Ophthalmol (Phila). 2017; 6(6): 546–553.
  4. Ricci F, Bandello F, Navarra P, et al. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Int J Mol Sci. 2020; 21(21).
  5. Salo D, Eget D, Lavery RF, et al. Can patients accurately read a visual analog pain scale? Am J Emerg Med. 2003; 21(7): 515–519.
  6. Yau GL, Jackman CS, Hooper PL, et al. Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial. Am J Ophthalmol. 2011; 151(2): 333–7.e2.
  7. Cintra LP, Lucena LR, Da Silva JA, et al. Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging. 2009; 40(1): 13–18.
  8. İnaltekin A, Bozkurt E, Kıvrak Y. Factors Associated with Pain Level in Patients Receiving Intravitreal Injection. J Curr Ophthalmol. 2021; 33(3): 323–329.
  9. Loureiro M, Matos R, Sepulveda P, et al. Intravitreal Injections of Bevacizumab: The Impact of Needle Size in Intraocular Pressure and Pain. J Curr Glaucoma Pract. 2017; 11(2): 38–41.
  10. Kampougeris G, Spyropoulos D, Mitropoulou A. Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and Correlations. J Curr Glaucoma Pract. 2013; 7(1): 19–24.
  11. Amoaku W, Pearce I, Browning A. Guidelines for Intravitreal Injections Procedure 2009 . The Royal College of Ophthalmologists , London 2009.
  12. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011; 151(2): 329–332.
  13. Yannuzzi NA, Patel SN, Bhavsar KV, et al. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014; 158(2): 319–327.e2.
  14. Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008; 146(6): 930–934.e1.
  15. Lemos V, Cabugueira A, Noronha M, et al. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections. Ophthalmologica. 2015; 233(3-4): 162–168.
  16. Pang CE, Mrejen S, Hoang QV, et al. Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina. 2015; 35(7): 1401–1406.
  17. Moisseiev E, Regenbogen M, Bartfeld Y, et al. Evaluation of pain in intravitreal bevacizumab injections. Curr Eye Res. 2012; 37(9): 813–817.
  18. Zhou NL, Gao YJ, An J, et al. Tunnelled scleral intravitreal injection with vitreous reflux assessed by AS-OCT. Int J Clin Exp Med. 2016; 9(7): 12959-–12963.
  19. Knecht PB, Michels S, Sturm V, et al. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina. 2009; 29(8): 1175–1181.
  20. Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003; 4(7): 407–414.
  21. Güler M, Bilgin B, Çapkın M, et al. Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean J Ophthalmol. 2015; 29(3): 190–194.
  22. Rodrigues EB, Grumann A, Penha FM, et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther. 2011; 27(2): 197–203.
  23. Haas P, Falkner-Radler C, Wimpissinger B, et al. Needle size in intravitreal injections - pain evaluation of a randomized clinical trial. Acta Ophthalmol. 2016; 94(2): 198–202.
  24. Rifkin L, Schaal S. Factors affecting patients' pain intensity during in office intravitreal injection procedure. Retina. 2012; 32(4): 696–700.
  25. Eaton AM, Gordon GM, Wafapoor H, et al. Assessment of novel guarded needle to increase patient comfort and decrease injection time during intravitreal injection. Ophthalmic Surg Lasers Imaging Retina. 2013; 44(6): 561–568.
  26. Pulido JS, Zobitz ME, An KN. Scleral penetration force requirements for commonly used intravitreal needles. Eye (Lond). 2007; 21(9): 1210–1211.
  27. Doguizi S, Sekeroglu MA, Inanc M, et al. Evaluation of pain during intravitreal aflibercept injections. Eur J Ophthalmol. 2018; 28(1): 63–67.